ACELYRIN Says Phase 3 Trial Of Izokibep In Hidradenitis Suppurativa Met Primary Endpoint Of HiSCR75 At 12 Weeks
Portfolio Pulse from Benzinga Newsdesk
ACELYRIN announced that its Phase 3 trial of Izokibep in Hidradenitis Suppurativa met the primary endpoint of HiSCR75 at 12 weeks. The company also reported having $635.2 million in cash, cash equivalents, and short-term marketable securities as of June 30, 2024, which is projected to extend its cash runway to mid-2027.
August 13, 2024 | 8:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ACELYRIN's Phase 3 trial of Izokibep in Hidradenitis Suppurativa met its primary endpoint, and the company has a strong cash position projected to last until mid-2027.
Meeting the primary endpoint in a Phase 3 trial is a significant milestone that can lead to regulatory approval and commercialization, positively impacting the stock price. Additionally, a strong cash position ensures financial stability and supports further development.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100